Oncoinvent ASA (BRRGF) Price & Analysis

Q: What was Oncoinvent ASA’s price range in the past 12 months?

Oncoinvent ASA lowest stock price was $0.03 and its highest was $0.03 in the past 12 months.

Q: What is Oncoinvent ASA’s market cap?

Oncoinvent ASA’s market cap is $38.71M.

Q: When is Oncoinvent ASA’s upcoming earnings report date?

Oncoinvent ASA’s upcoming earnings report date is Aug 27, 2026 which is in 19 days.

Q: Is Oncoinvent ASA overvalued?

According to Wall Street analysts Oncoinvent ASA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Oncoinvent ASA pay dividends?

Oncoinvent ASA does not currently pay dividends.

Q: What is Oncoinvent ASA’s EPS estimate?

Oncoinvent ASA’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Oncoinvent ASA have?

Oncoinvent ASA has 4,478,411 shares outstanding.

Q: Which hedge fund is a major shareholder of Oncoinvent ASA?

Currently, no hedge funds are holding shares in BRRGF

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

59 Followers

BRRGF Stock Chart & Stats

$0.02

$0.00(0.00%)

At close: Nov 29 4:00 PM EST

$0.02

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.03 - $0.03

Previous CloseN/A

Volume10.00

Average Volume (3M)0.00

Market Cap

$38.71M

Enterprise Value-$99.84

Total Cash (Recent Filing)$140.16M

Total Debt (Recent Filing)$818.00K

Price to Earnings (P/E)―

Beta0.00

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.55

Shares Outstanding4,478,411

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap>-0.01

Enterprise Value/Revenue>-0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda<0.01

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Oncoinvent ASA News

Oncoinvent Hits 50% Enrollment in Phase 2 Radspherin Trial for Ovarian Cancer

An update from Oncoinvent ASA ( ($BRRGF) ) is now available. Oncoinvent has reached the halfway point in...

2M ago

Oncoinvent Aligns Board Incentives with Equity Grants as Radspherin Advances

The latest announcement is out from Oncoinvent ASA ( ($BRRGF) ). Oncoinvent ASA has implemented a new share-based...

3M ago

Oncoinvent Clears AGM Agenda as It Pushes Radspherin Toward Post-Surgical Cancer Market

Oncoinvent ASA ( ($BRRGF) ) has shared an announcement. Oncoinvent ASA, a Norwegian radiopharmaceutical developer, is advancing Radspherin,...

3M ago

Oncoinvent Finalizes Major Share Capital Reduction Amid Progress on Cancer Therapy Radspherin

The latest announcement is out from Oncoinvent ASA ( ($BRRGF) ). Oncoinvent ASA has completed a substantial share...

3M ago

Oncoinvent Advances Radspherin Program With New Patent, Phase 2 Recruitment and CFO Hire

Oncoinvent ASA ( ($BRRGF) ) has provided an update. Oncoinvent ASA, a Norwegian biotech, is developing Radspherin, a...

3M ago

Oncoinvent Sets Virtual AGM as Radspherin Development Advances

Oncoinvent ASA ( ($BRRGF) ) just unveiled an update. Oncoinvent ASA has called its 2026 annual general meeting...

3M ago

Oncoinvent Sets April Webcast as Radspherin Program Gains Momentum

Oncoinvent ASA ( ($BRRGF) ) has issued an announcement. Oncoinvent ASA will host a live webcast for investors,...

4M ago

Oncoinvent Publishes 2025 Annual Report as Radspherin Program Advances

Oncoinvent ASA ( ($BRRGF) ) has provided an update. Oncoinvent ASA has published its 2025 annual report after...

4M ago

Oncoinvent Secures Key Chinese Patent for Lead Radiopharmaceutical Radspherin

An update from Oncoinvent ASA ( ($BRRGF) ) is now available. Oncoinvent has secured its first patent from...

5M ago

Oncoinvent Grants CEO New Share Options as It Advances Radiopharmaceutical Pipeline

An announcement from Oncoinvent ASA ( ($BRRGF) ) is now available. Oncoinvent ASA’s board has granted CEO Øystein...

5M ago

BerGenBio target adjusted to NOK 38 from NOK 70 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on BerGenBio to NOK 38 from NOK 70...

2y ago

BerGenBio downgraded to Sell on ‘detrimental’ financing at DNB

DNB Markets analyst Geir Hiller Holom downgraded BerGenBio to Sell from Hold with a price target of NOK...

3y ago

BerGenBio downgraded to Sell from Hold at DNB Markets

DNB Markets downgraded BerGenBio to Sell from Hold with a NOK 1 price target. Published first on TheFly...

3y ago

BerGenBio upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis upgraded BerGenBio to Buy from Neutral with a NOK 30 price target. "Now...

4y ago

BRRGF

BRRGF FAQ

What was Oncoinvent ASA’s price range in the past 12 months?

Oncoinvent ASA lowest stock price was $0.03 and its highest was $0.03 in the past 12 months.

What is Oncoinvent ASA’s market cap?

Oncoinvent ASA’s market cap is $38.71M.

When is Oncoinvent ASA’s upcoming earnings report date?

Oncoinvent ASA’s upcoming earnings report date is Aug 27, 2026 which is in 19 days.

How were Oncoinvent ASA’s earnings last quarter?

Currently, no data Available

Is Oncoinvent ASA overvalued?

According to Wall Street analysts Oncoinvent ASA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Oncoinvent ASA pay dividends?

Oncoinvent ASA does not currently pay dividends.

What is Oncoinvent ASA’s EPS estimate?

Oncoinvent ASA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Oncoinvent ASA have?

Oncoinvent ASA has 4,478,411 shares outstanding.

What happened to Oncoinvent ASA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Oncoinvent ASA?

Currently, no hedge funds are holding shares in BRRGF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Oncoinvent ASA

Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to developing innovative radiopharmaceutical treatments for various cancers. Its primary therapeutic agent is Radspherin, an alpha-emitting radiotherapeutic, which is currently undergoing investigation in two Phase 1/2a and one randomized Phase 2 clinical trials. This promising candidate is designed to target and treat malignancies that have metastasized to body cavities, specifically including the peritoneum.